Nasdaq

Takeda Announces U.S. FDA Approval of GAMMAGARD LIQUID ERC, the Only Ready-to-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content¹

GAMMAGARD LIQUID ERC [immune globulin infusion (human)] with Less Than or Equal to 2 µg/mL IgA in a 10% Solution is Approved for Intravenous or Subcutaneous Use in People Aged Two and Older with ...
Nasdaq

FDA Approves ArbliTM, the First Ready-to-Use Oral Liquid Formulation of Losartan, from Scienture Holdings, Inc.

Scienture Holdings, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved its liquid formulation of losartan, branded as ArbliTM (losartan potassium) Oral Suspension, at a ...
Seeking Alpha

SCIENTURE Provides Commercial Update on ARBLI™, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium

COMMACK, NY, Feb. 03, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to ...
News Medical

Analytichem introduces Redipor® ready-to-use culture media brand globally

AnalytiChem, manufacturer of specialized laboratory equipment, reagents and consumables, has introduced Redipor ® ready-to-use culture media as an AnalytiChem branded product line globally. Built on ...
Morningstar

Takeda Announces U.S. Availability of GAMMAGARD LIQUID ERC, the Only Ready-to-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content1

Takeda Announces U.S. Availability of GAMMAGARD LIQUID ERC, the Only Ready-to-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content1 − GAMMAGARD LIQUID ERC [immune globulin ...